
    trial was terminated by sponsor due to lack of efficacy.
  
['head and neck neoplasms']
['patritumab', 'cetuximab', 'cisplatin', 'carboplatin', 'placebo']

        Inclusion Criteria:

          -  Has histologically confirmed recurrent disease or metastatic SCCHN tumor and/or from
             its lymph nodal metastases originating from the oral cavity, oropharynx, hypopharynx,
             and larynx

          -  Has or be willing to provide tumor tissue for testing

          -  Has measurable disease per Response Evaluation Criteria in Solid Tumor (RECIST)
             version 1.1

          -  Has Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Has adequate hematological function per protocol

          -  Has adequate renal function per protocol

          -  Has adequate hepatic function per protocol

          -  Agrees to use effective contraception while on the study and for 6-months after the
             end of the study

          -  Provides written informed consent(s)

        Exclusion Criteria:

          -  Has left ventricular ejection fraction (LVEF) <50%

          -  Had prior epidermal growth factor receptor (EGFR) targeted regimen

          -  Had prior anti-human epidermal growth factor receptor 3 (anti-HER3) therapy

          -  Had prior chemotherapy for recurrent/metastatic disease

          -  Had anti-cancer therapy between biopsy and submission of sample

          -  Has history of other malignancies, except adequately treated non-melanoma skin cancer,
             curatively treated in-situ disease, or other solid tumors curatively treated with no
             evidence of disease for ≥ 2 years

          -  Has known history of brain metastases or active brain metastases

          -  Has uncontrolled hypertension

          -  Has clinically significant electrocardiograph (ECG) findings

          -  Had myocardial infarction within 1 year before enrollment, symptomatic congestive
             heart failure, unstable angina, or arrhythmia requiring medication

          -  Had platinum-containing drug therapy with radiotherapy less than 6 months before study
             drug treatment

          -  Had therapeutic or palliative radiation therapy or major surgery within 4 weeks before
             study drug treatment
      